ArticleCell2019
Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 364 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
364citing papers in PubMed, 1 pooled it
33.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
364 citing papers in PubMed, 1 synthesis or guideline pooled it, 527 citations in OpenAlex.
- Global research trends and hotspots in prognostic prediction models for pancreatic cancer: a bibliometric analysis.Frontiers in oncology · 2025Pooled it
- Trial
- Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer.Cancer immunology research · 2026Article
- Epigenetic reprogramming of lineage switching in cancer.FEBS letters · 2026Review
- Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis.Oncogene · 2026Article
- Developmental and MAPK-responsive transcription factors regulate distinct malignant cell states and associated genetic dependencies in pancreatic cancer.Nature genetics · 2026Article
- Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma.NPJ precision oncology · 2026Article
- CAFs shape the immunosuppressive microenvironment of pancreatic cancer through the Lin28b-STING Axis.Nature communications · 2026Article
- Spatially resolved tissue architecture and computational pathology in pancreatic cancer.Experimental & molecular medicine · 2026Review
- Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer.Cancer research · 2026Article
- Review
- Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer.Nature communications · 2026Article
- Article
- Rapid autofluorescence based 3D optical imaging of the pancreatic cancer milieu at mesoscopic scale - stain-free volumetric segmentation.Scientific reports · 2026Article
- Extrapancreatic extension modifies chemotherapy benefit in resected pancreatic ductal adenocarcinoma: a population-based cohort study.Scientific reports · 2026Article
- Context defines precision: rethinking KRAS inhibition in oncology.NPJ precision oncology · 2026Review
- A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma.Scientific reports · 2026Article
- Computational Modeling of Cellular Influence Delineates Functionally Relevant and Distinct Cellular Neighborhoods in Primary and Metastatic Pancreatic Ductal Adenocarcinoma.Cancer immunology research · 2026Article
- Cancer-Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment.Nature reviews. Cancer · 2026Review
304 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
48 authors at 5 institutions in 2 countries.
Matteo LigorioCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
Srinjoy SilCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Jose Malagon-LopezCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Linda T NiemanCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Sandra MisaleCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Mauro Di PilatoDivision of Rheumatology, Allergy, and Immunology, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02114, USA.
Richard Y EbrightCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Murat N KarabacakCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Center for Engineering in Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02114, USA.
Anupriya S KulkarniCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Ann LiuCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Nicole Vincent JordanCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Joseph W FransesCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Julia PhilippCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Johannes KreuzerCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Niyati DesaiCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Kshitij S AroraCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Mihir RajurkarCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Elad HorwitzCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Azfar NeyazCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Eric TaiCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Neelima K C MagnusCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Kevin D VoCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Chittampalli N YashaswiniCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Francesco MarangoniDivision of Rheumatology, Allergy, and Immunology, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02114, USA.
Myriam BoukhaliCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Jackson P FatherreeCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Leah J DamonCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Kristina XegaCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Rushil DesaiCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Melissa ChozCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Francesca BersaniCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Adam LangenbucherCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Vishal ThaparCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Robert MorrisCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Ulrich F WellnerClinic of Surgery, UKSH Campus Lübeck, Germany.
Oliver SchillingInstitute of Pathology, University Medical Center Freiburg, Germany.
Michael S LawrenceCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Andrew S LissDepartment of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
Miguel N RiveraCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Vikram DeshpandeCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Cyril H BenesCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Shyamala MaheswaranCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
Daniel A HaberCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Division of Rheumatology, Allergy, and Immunology, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02114, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Carlos Fernandez-Del-CastilloCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
Cristina R FerroneCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
Wilhelm HaasCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Martin J AryeeCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. Electronic address: aryee.martin@mgh.harvard.edu.
David T TingCancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: dting1@mgh.harvard.edu.
Massachusetts General Hospital · USHarvard University · USHoward Hughes Medical Institute · USUniversitäres Kinderwunschzentrum Lübeck · DEUniversity Medical Center Freiburg · DE
Funding
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MMOUNT SINAI MEDICAL SCIENTIST TRAINING PROGRAMT32GM007280 · NIGMS · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BARON, MARGARET H · 1985 to 2021
$22.8MPoint-of care Microfluidics for Early Detection of CancerU01EB012493 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI HABER, DANIEL A., TONER, MEHMET · 2010 to 2018
$19.6MTraining Program in Cancer Biology and TherapeuticsT32CA071345 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber, Lecia V. Sequist · 1997 to 2026
$10.6MModeling Metastasis and Acquired Drug Resistance Using Circulating Tumor CellsR01CA129933 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber · 2008 to 2026
$7.5MSystems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacyU01CA215798 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HAAS, WILHELM, HAIGIS, KEVIN · 2017 to 2021
$3.7MMechanistic Understanding for the Role of Lin28b in Pancreatic Cancer ProgressionR01CA235412 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EL-BARDEESY, NABEEL, MOSTOSLAVSKY, RAUL · 2019 to 2023
$3.2MMetastasis and biophysics of clusters of circulating tumor cells in the microcirculationU01CA214297 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HABER, DANIEL A., MAHESWARAN, SHYAMALA · 2018 to 2022
$2.9MGenome-scale CRISPR activation screening to identify lung-specific metastatic pathwaysF30CA232407 · NCI · HARVARD MEDICAL SCHOOL · PI EBRIGHT, RICHARD · 2018 to 2020
$118kHoward Hughes Medical InstituteNCI NIH HHS F30 CA232407NCI NIH HHS R01 CA129933NCI NIH HHS R01 CA235412NCI NIH HHS T32 CA071345NCI NIH HHS U01 CA214297NCI NIH HHS U01 CA215798NIBIB NIH HHS U01 EB012493NIGMS NIH HHS T32 GM007280NIGMS NIH HHS T32 GM007753
Abstract
Single-cell technologies have described heterogeneity across tissues, but the spatial distribution and forces that drive single-cell phenotypes have not been well defined. Combining single-cell RNA and protein analytics in studying the role of stromal cancer-associated fibroblasts (CAFs) in modulating heterogeneity in pancreatic cancer (pancreatic ductal adenocarcinoma [PDAC]) model systems, we have identified significant single-cell population shifts toward invasive epithelial-to-mesenchymal transition (EMT) and proliferative (PRO) phenotypes linked with mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) signaling. Using high-content digital imaging of RNA in situ hybridization in 195 PDAC tumors, we quantified these EMT and PRO subpopulations in 319,626 individual cancer cells that can be classified within the context of distinct tumor gland "units." Tumor gland typing provided an additional layer of intratumoral heterogeneity that was associated with differences in stromal abundance and clinical outcomes. This demonstrates the impact of the stroma in shaping tumor architecture by altering inherent patterns of tumor glands in human PDAC.
Indexed as
Tumor MicroenvironmentAnimalsCancer-Associated FibroblastsCarcinoma, Pancreatic DuctalCell ProliferationCoculture TechniquesEpithelial-Mesenchymal TransitionFemaleHEK293 CellsHeterograftsHumansMiceMice, Inbred NODMice, SCIDMitogen-Activated Protein KinasesPancreatic NeoplasmsMitogen-Activated Protein KinasesSTAT3 protein, humanSTAT3 Transcription Factormass spectrometrypancreatic cancerpancreatic ductal adenocarcinomasingle cell RNA-sequencingsingle cell spatial analysisstromal microenvironmenttumor architecture
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.